Task B1 · evidence aggregation
What experimental evidence in the corpus supports a mechanistic link between mutant p53 and immune suppression?
Gold evidence
Acceptable answer concepts
- mutant p53 binds TBK1
- blocks STING-TBK1-IRF3 axis
- immune evasion
Construction note
Directly restates the mechanism described in PMID:42700791's abstract (mutp53 binding TBK1, blocking STING-TBK1-IRF3 signaling).
How each architecture answered
Baseline 0 · no retrieval
Yuu no Sekai · 435 tokens · 2.7s(abstained) No experimental evidence was retrieved to support a mechanistic link between mutant p53 and immune suppression.
There is no experimental evidence in the corpus supporting a mechanistic link between mutant p53 and immune suppression.
Baseline 1 · retrieve + synthesize
Yuu no Sekai · 2545 tokens · 6.5sExperimental evidence from the corpus supports a mechanistic link between mutant p53 and immune suppression through its interaction with TANK-binding kinase 1 (TBK1). This interaction blocks the formation of the STING-TBK1-interferon regulatory factor 3 (IRF3) signaling complex, which is essential for inducing Type I interferon (IFN-I) production. As a result, the anti-tumor immune response is weakened.
Mutant p53 suppresses the immune system by binding to TANK-binding kinase 1 (TBK1).
The interaction between mutant p53 and TBK1 blocks the formation of the STING-TBK1-IRF3 signaling complex.
This interaction leads to weakened anti-tumor immune response by inhibiting Type I interferon (IFN-I) production.
Agent 1 · planner + retrieve + synthesize
Yuu no Sekai · 2638 tokens · 7.3sExperimental evidence from the corpus supports a mechanistic link between mutant p53 and immune suppression by showing that mutant p53 suppresses the immune system by binding to TANK-binding kinase 1 (TBK1), blocking the formation of the STING-TBK1-IRF3 signaling complex, which is essential for inducing Type I interferon (IFN-I) production, thereby weakening the anti-tumor immune response.
Mutant p53 suppresses the immune system by binding to TANK-binding kinase 1 (TBK1).
The interaction between mutant p53 and TBK1 blocks the formation of the STING-TBK1-IRF3 signaling complex.
This blockage inhibits Type I interferon (IFN-I) production, leading to a weakened anti-tumor immune response.